A clinical study of Tasimelteon (HETLIOZ) fro treatment of delayed sleep phase disorder (DSPD) in patients who have a mutation in the CRY1 gene
Latest Information Update: 04 Mar 2019
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Therapeutic Use
Most Recent Events
- 04 Mar 2019 New trial record
- 13 Feb 2019 According to a media release, the company plans to initate this phase 2 study in the third quarter of 2019.